nChroma
nChroma Bio is a clinical-stage genetic medicines company developing targeted in vivo delivery systems and engineered epigenetic silencers for durable disease treatment. Its lead program, CRMA-1001, is a liver-directed epigenetic therapy in Phase 1/2 trials targeting a functional cure for chronic hepatitis B. The company combines lipid nanoparticle delivery with proprietary epigenetic editing to achieve durable gene silencing without altering the underlying DNA sequence.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2024
Mar 2023
Nov 2021
Create a free account to see which investors have funded this company.
Create Free Account
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Long-read DNA sequencing company providing advanced systems for complete and accurate genome, tra...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
